Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Two androgen receptor inhibitors improved survival by 33% in men with metastatic prostate cancer that responds to hormone therapy.
Building on this discovery, researchers have designed a new treatment that showed promise in a study of mice.
The American Society of Clinical Oncology has released new prostate cancer guidelines.
Erleada delayed cancer progression and death by two years in a Phase III trial.
Erleada prolonged the time to disease progression or death in the SPARTAN trial.
Xtandi and Erleada both prolonged the time to disease progression or death by about two years.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.